RADICAL CYSTECTOMY FOR PRIMARY NEUROENDOCRINE TUMORS OF THE BLADDER: THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE
- 1 July 2005
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 174 (1), 93-96
- https://doi.org/10.1097/01.ju.0000162085.20043.1f
Abstract
Primary neuroendocrine tumors of the bladder are rare and they include small and large cell variants. We reviewed our experience with treating these tumors with radical cystectomy to evaluate their histopathological characteristics and clinical outcomes. From August 1971 to June 2004, 2,005 patients underwent radical cystectomy for primary bladder cancer at our institution, of whom 25 (1.2%) had neuroendocrine tumors of the bladder, including small cell carcinoma in 20 and large cell carcinoma in 5. Pure neuroendocrine-type histology was identified in 16 cases, including 1 with small and large cell features, while the remaining 9 had mixed histology, that is transitional cell carcinoma in 8 and adenocarcinoma in 1. Multi-agent chemotherapy was administered to 14 patients. Median patient age was 68 years (range 40 to 82) and 19 patients were male (76%). A total of 19 patients (76%) had lymph node involvement, of whom 2 had small liver metastases found intraoperatively, while only 4 (16%) had organ confined tumors and 2 (8%) had extravesical, node negative disease. These tumors tended to have a flat, ulcerative gross appearance with lymphovascular invasion, carcinoma in situ and necrosis present microscopically. Median followup was 11.8 years (range 18 days to 15.1 years). Five-year overall and recurrence-free survival was 10% and 13%, respectively. There was no significant survival difference between small and large cell carcinoma. Mixed histologies tended to do better than pure neuroendocrine tumors, although this did not attain statistical significance (p = 0.064). Patients receiving multimodality therapy had significantly better overall (p = 0.051) and recurrence-free (p = 0.003) survival than those treated with cystectomy alone. Neuroendocrine tumors of the bladder usually present with advanced pathological stage and portend a poor prognosis. Adjuvant chemotherapy protocols may provide improved survival compared with cystectomy alone.Keywords
This publication has 14 references indexed in Scilit:
- Analysis of treatment for small cell cancer of the bladder and report of three casesUrology, 2004
- Small cell carcinoma of the urinary bladderCancer, 2004
- EVIDENCE SUPPORTING PREOPERATIVE CHEMOTHERAPY FOR SMALL CELL CARCINOMA OF THE BLADDER: A RETROSPECTIVE REVIEW OF THE M. D. ANDERSON CANCER EXPERIENCEJournal of Urology, 2004
- Small cell carcinoma of the bladderBJU International, 2004
- Primary large cell neuroendocrine carcinoma of the urinary bladder.Archives of Pathology & Laboratory Medicine, 2002
- Small Cell Carcinoma of the Urinary BladderEuropean Urology, 2001
- Small Cell Carcinoma of the Urinary Bladder Treated with Chemotherapy and Radiotherapy: Results in Five CasesEuropean Urology, 1999
- GENITOURINARY SMALL CELL CARCINOMA: DETERMINATION OF CLINICAL AND THERAPEUTIC FACTORS ASSOCIATED WITH SURVIVALJournal of Urology, 1998
- Small cell carcinoma of the bladder and prostateUrology, 1995
- Advanced small cell carcinoma of the bladder successful treatment with combined radical cystoprostatectomy and adjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapyCancer, 1990